Shanghai Targetdrug Ltd. (hereinafter referred to as "TD") was founded in 2003 by Shanghai Institutes for Biological Sciences of Chinese Academy of Sciences, Shanghai Institute of Organic Chemistry and Shanghai Fudan Zhangjiang Biology Pharmaceutical Company Limited.

New Drug R & D Since inception, TD is committed to innovation in small molecule drug discovery and development. In the technology field, TD is mainly concentrated in the G protein-coupled receptors, in particular chemokine receptor-related diseases, such as the treatment and prevention of HIV infection, autoimmune diseases, etc.

Drug Screening Services Meanwhile adhering to independent innovation in drug development, TD has established a domestic leading drug screening and early evaluation platform. In order to allow these technologies to make full use of resources, and create greater value, the target company to provide domestic and foreign R & D counterparts relevant GPCR drug screening and early evaluation of services. There are currently dozens of GPCR receptors screening model available.

Our Advantages As a company with rich experience in international cooperation and effective project management team, we are familiar with new drug research and development processes and operation models, and good at the integration of domestic resources. After these years’ research and development， we have achieved the credibility in the market. In addition, we could further utilize the technical resources from the shareholders and other scientists to maximize the value of the R&D results, in order to break through the R & D bottlenecks of the biotech companies.

Technology complementation and the project co-operation in new drug R & D are the inevitable trends of the industry. TD has attached great importance to the co-operations with a variety of domestic and foreign entities, including the Shanghai Institutes for Biological Sciences, Shanghai Institute of Organic Chemistry of Chinese Academy of Sciences, the National Center for Drug Screening, as well as foreign R & D companies.